AGÕæÈ˹ٷ½

STOCK TITAN

Healthpeak Properties Reports Second Quarter 2025 Results

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

DENVER--(BUSINESS WIRE)-- Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the quarter ended June 30, 2025.

SECOND QUARTER 2025 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS

  • Net income of $0.05 per share, Nareit FFO of $0.43 per share, FFO as Adjusted of $0.46 per share, AFFO of $0.44 per share, and Total Merger-Combined Same-Store Cash (Adjusted) NOI growth of 3.5%
  • On July 7, 2025, declared a monthly common stock cash dividend of $0.10167 per share for each of July, August, and September, of 2025 representing cash dividends totaling $0.305 per share for the third quarter, and an annualized dividend amount of $1.22 per share
  • Second quarter new and renewal lease executions totaled 1.5 million square feet:
    • Outpatient medical new and renewal lease executions totaled 1 million square feet, with 85% retention and +6% cash releasing spreads on renewals
      • Subsequent to the second quarter and through July 24, 2025, executed 419,000 square feet of Outpatient medical leases with signed letters of intent on an additional 682,000 square feet
    • Lab new and renewal lease executions totaled 503,000 square feet, with 87% retention and +6% cash releasing spreads on renewals
      • Subsequent to the second quarter and through July 24, 2025, executed 55,000 square feet of Lab leases with signed letters of intent on an additional 253,000 square feet
  • During the second quarter, entered into two new development agreements with a combined projected cost of $148 million to support Northside Hospital’s continued outpatient expansion in the Atlanta market
  • Sold one outpatient medical land parcel in June 2025 and two outpatient medical buildings in July 2025 for combined proceeds of approximately $35 million
  • Balance Sheet
    • Net Debt to Adjusted EBITDAre was 5.2x for the quarter ended June 30, 2025
    • As of July 24, 2025, Healthpeak had approximately $2.3 billion in available liquidity through a combination of unrestricted cash and availability under its revolving credit facility
  • Launched a redesigned corporate website at to elevate visibility into Healthpeak’s competitive advantage and core values
  • Earned 2025 BOMA Mid Atlantic region TOBY Awards for 833 Chestnut Street (medical category) and Cambridge Discovery Park (life science category); TOBY (The Outstanding Building of the Year) Awards are among the most prestigious recognitions in commercial real estate, honoring commercial building management and operations excellence
  • Recent corporate impact and sustainability achievements include:
    • Published a standalone 2024 Environmental Data Report, marking our 14th consecutive year of environmental performance transparency and reporting
    • Awarded the Green Lease Leader Platinum designation by the Institute for Market Transformation and the Department of Energy Better Buildings Alliance
    • Earned LEED Gold certifications for sustainable building design and construction at Callan Ridge in Torrey Pines, California, and 460 Forbes on the Vantage campus in South San Francisco, California, bringing Healthpeak's total LEED-certified square footage to 6.7 million as of June 30, 2025
    • Named a constituent of the FTSE4Good Index Series for the 14th consecutive year

To learn more about Healthpeak's commitment to responsible business and view our most recent Corporate Impact Report, please visit .

SECOND QUARTER COMPARISON

Ìý

Three Months Ended
June 30, 2025

Ìý

Three Months Ended
June 30, 2024

(in thousands, except per share amounts)

Amount

Ìý

Per Share

Ìý

Amount

Ìý

Per Share

Net income, diluted

$

31,558

Ìý

$

0.05

Ìý

$

145,904

Ìý

$

0.21

Nareit FFO, diluted

Ìý

308,167

Ìý

Ìý

0.43

Ìý

Ìý

318,610

Ìý

Ìý

0.44

FFO as Adjusted, diluted

Ìý

325,785

Ìý

Ìý

0.46

Ìý

Ìý

320,220

Ìý

Ìý

0.45

AFFO, diluted

Ìý

314,768

Ìý

Ìý

0.44

Ìý

Ìý

289,064

Ìý

Ìý

0.40

YEAR TO DATE COMPARISON

Ìý

Six Months Ended
June 30, 2025

Ìý

Six Months Ended
June 30, 2024

(in thousands, except per share amounts)

Amount

Ìý

Per Share

Ìý

Amount

Ìý

Per Share

Net income, diluted

$

73,922

Ìý

$

0.11

Ìý

$

152,345

Ìý

$

0.23

Nareit FFO, diluted

Ìý

631,447

Ìý

Ìý

0.89

Ìý

Ìý

479,906

Ìý

Ìý

0.72

FFO as Adjusted, diluted

Ìý

655,498

Ìý

Ìý

0.92

Ìý

Ìý

597,879

Ìý

Ìý

0.90

AFFO, diluted

Ìý

621,185

Ìý

Ìý

0.87

Ìý

Ìý

544,101

Ìý

Ìý

0.82

Nareit FFO, FFO as Adjusted, AFFO, Total Merger-Combined Same-Store Cash (Adjusted) NOI, and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts (see the "Funds From Operations" and "Adjusted Funds From Operations" sections of this release for additional information). See "June 30, 2025 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP in the Investor Relations section of our website at .

MERGER-COMBINED SAME-STORE ("SS") OPERATING SUMMARY

The table below outlines the year-over-year three-month and year-to-date total Merger-Combined SS Cash (Adjusted) NOI growth.

Year-Over-Year Total Merger-Combined SS Cash (Adjusted) NOI Growth

Ìý

Ìý

Ìý

Ìý

Three Month

Ìý

Year-To-Date

Ìý

SS Growth %

% of SS

Ìý

SS Growth %

% of SS

Outpatient Medical

3.9

%

55.2

%

Ìý

4.5

%

54.9

%

Lab

1.5

%

34.4

%

Ìý

5.4

%

34.5

%

CCRC

8.6

%

10.4

%

Ìý

12.2

%

10.6

%

Total Merger-Combined SS Cash (Adjusted) NOI

3.5

%

100.0

%

Ìý

5.6

%

100.0

%

DIVIDEND

On July 7, 2025, Healthpeak's Board of Directors declared a monthly common stock cash dividend of $0.10167 per share for each of July, August, and September, of 2025 representing cash dividends totaling $0.305 per share for the third quarter, and an annualized dividend amount of $1.22 per share. The dividend is payable on the payment dates set forth in the table below to stockholders of record as of the close of business on the corresponding record date.

Record Date

Payment Date

Amount

July 18, 2025

July 31, 2025

$0.10167 per common share

August 18, 2025

August 29, 2025

$0.10167 per common share

September 19, 2025

September 30, 2025

$0.10167 per common share

NORTHSIDE OUTPATIENT MEDICAL DEVELOPMENTS

During the second quarter of 2025, Healthpeak entered into two new outpatient development agreements in high-growth submarkets of Atlanta totaling $148 million to support the expansion of our longstanding partner, Northside Hospital. Affiliates of Northside have pre-leased 78% of each building for a range of clinical services, reflecting the system’s continued investment in outpatient capacity across two premier campuses. Physician tenants will have the ability to co-invest in the buildings. Upon stabilization, Healthpeak expects to achieve cash yields in the mid-7% range.

  • Northside Forsyth: $82 million, 118,000 square foot Class A outpatient medical building and accompanying parking deck located on the campus of Northside Hospital Forsyth, a 389-bed acute care hospital located in Cumming, Georgia, a northeastern suburb of Atlanta.
  • Northside Cherokee: $66 million, 148,000 square foot Class A outpatient medical building located on the campus of Northside Hospital Cherokee, a 332-bed acute care hospital in Canton, Georgia, a northern suburb of Atlanta.

SHARE REPURCHASE ACTIVITY

As previously disclosed, in April 2025, Healthpeak repurchased 3.9 million shares at a weighted average share price of $18.22, totaling $72 million.

As of July 24, 2025, approximately $406 million remained available for share repurchases under the program.

BALANCE SHEET

In June 2025, Healthpeak repaid $452 million 4.0% senior notes at maturity.

As of July 24, 2025, Healthpeak had approximately $2.3 billion in available liquidity through a combination of unrestricted cash and its revolving credit facility.

2025 GUIDANCE

We are reaffirming the following guidance ranges for full year 2025:

  • Diluted FFO as Adjusted per share of $1.81 â€� $1.87
  • Total Merger-Combined Same-Store Cash (Adjusted) NOI growth of 3.0% â€� 4.0%

We are updating the following guidance ranges for full year 2025:

  • Diluted earnings per common share from $0.30 â€� $0.36 to $0.25 â€� $0.31
  • Diluted Nareit FFO per share from $1.81 â€� $1.87 to $1.78 â€� $1.84

These estimates are based on our current view of existing market conditions, transaction timing, and other assumptions for the year ending December 31, 2025. For additional details and assumptions, please see page 12 in our corresponding Supplemental Report and the Discussion and Reconciliation of Non-GAAP Financial Measures, both of which are available in the Investor Relations section of our website at .

CONFERENCE CALL INFORMATION

Healthpeak has scheduled a conference call and webcast for Friday, July 25, 2025, at 8:00 a.m. Mountain Time.

The conference call can be accessed in the following ways:

  • Healthpeak’s website:
  • Webcast: . Joining via webcast is recommended for those who will not be asking questions.
  • Telephone: The participant dial-in number is (800) 715-9871

An archive of the webcast will be available on Healthpeak’s website through July 24, 2026, and a telephonic replay can be accessed through August 1, 2025, by dialing (800) 770-2030 and entering conference ID number 95156.

ABOUT HEALTHPEAK

Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate focused on healthcare discovery and delivery.

FORWARD-LOOKING STATEMENTS

Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, developments, redevelopments, joint venture transactions, leasing activity and commitments, financing activities, or other transactions discussed in this release; (ii) the payment of a quarterly cash dividend; and (iii) the information presented under the heading "2025 Guidance Information." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: macroeconomic trends that may increase construction, labor and other operating costs; changes within the life science industry; significant regulation, funding requirements, and uncertainty faced by our lab tenants; factors adversely affecting our tenantsâ€�, operatorsâ€�, or borrowersâ€� ability to meet their financial and other contractual obligations to us; the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in that specific sector than if we invested across multiple sectors; the illiquidity of real estate investments; our ability to identify and secure new or replacement tenants and operators; our property development, redevelopment, and tenant improvement risks, which can render a project less profitable or unprofitable and delay or prevent its undertaking or completion; the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable; our ability to develop, maintain, or expand hospital and health system client relationships; operational risks associated with our senior housing properties managed by third parties, including our properties operated through structures permitted by the Housing and Economic Recovery Act of 2008, which includes most of the provisions previously proposed in the REIT Investment Diversification and Empowerment Act of 2007 (commonly referred to as “RIDEAâ€�); economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments; uninsured or underinsured losses, which could result in a significant loss of capital invested in a property, lower than expected future revenues, and unanticipated expenses; our use of joint ventures may limit our returns on and our flexibility with jointly owned investments; our use of rent escalators or contingent rent provisions in our leases; competition for suitable healthcare properties to grow our investment portfolio; our ability to exercise rights on collateral securing our real estate-related loans; any requirement that we recognize reserves, allowances, credit losses, or impairment charges; investment of substantial resources and time in transactions that are not consummated; our ability to successfully integrate or operate acquisitions or internalize property management; the potential impact of unfavorable resolution of litigation or disputes and resulting rising liability and insurance costs; environmental compliance costs and liabilities associated with our real estate investments; our ability to satisfy environmental, social and governance and sustainability commitments and requirements, as well as stakeholder expectations; epidemics, pandemics, or other infectious diseases, including the coronavirus disease (Covid), and health and safety measures intended to reduce their spread; human capital risks, including the loss or limited availability of our key personnel; our reliance on information technology and any material failure, inadequacy, interruption, or security failure of that technology; the use of, or inability to use, artificial intelligence by us, our tenants, our vendors, and our investors; volatility, disruption, or uncertainty in the financial markets; increased borrowing costs, which could impact our ability to refinance existing debt, sell properties, and conduct investment activities; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; the availability of external capital on acceptable terms or at all; an increase in our level of indebtedness; covenants in our debt instruments, which may limit our operational flexibility, and breaches of these covenants; volatility in the market price and trading volume of our common stock; adverse changes in our credit ratings; the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety, and other regulations; laws or regulations prohibiting eviction of our tenants; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services; our participation in the Coronavirus, Aid, Relief and Economic Security Act Provider Relief Fund and other Covid-related stimulus and relief programs; changes in federal, state, or local laws or regulations that may limit our opportunities to participate in the ownership of, or investment in, healthcare real estate; our ability to successfully integrate our operations with Physicians AGÕæÈ˹ٷ½ty Trust and realize the anticipated synergies of our merger with Physicians AGÕæÈ˹ٷ½ty Trust and benefits of property management internalization; our ability to maintain our qualification as a real estate investment trust (“REITâ€�); our taxable REIT subsidiaries being subject to corporate level tax; tax imposed on any net income from “prohibited transactionsâ€�; changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; tax protection agreements that may limit our ability to dispose of certain properties and may require us to maintain certain debt levels; ownership limits in our charter that restrict ownership in our stock; provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders; conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP, LLC (“Healthpeak OPâ€�) common units; provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; our status as a holding company of Healthpeak OP; and other risks and uncertainties described from time to time in our Securities and Exchange Commission filings.

Moreover, other risks and uncertainties of which we are not currently aware may also affect our forward-looking statements, and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this communication are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they are subsequently made available by us on our website or otherwise. We do not undertake any obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

Ìý

Healthpeak Properties, Inc.

Consolidated Balance Sheets

In thousands, except share and per share data

Ìý

Ìý

June 30,
2025

Ìý

December 31,
2024

Assets

Ìý

Ìý

Ìý

AGÕæÈ˹ٷ½ estate:

Ìý

Ìý

Ìý

Buildings and improvements

$

16,211,931

Ìý

Ìý

$

16,115,283

Ìý

Development costs and construction in progress

Ìý

1,027,119

Ìý

Ìý

Ìý

880,393

Ìý

Land and improvements

Ìý

2,930,060

Ìý

Ìý

Ìý

2,918,758

Ìý

Accumulated depreciation and amortization

Ìý

(4,349,056

)

Ìý

Ìý

(4,083,030

)

Net real estate

Ìý

15,820,054

Ìý

Ìý

Ìý

15,831,404

Ìý

Loans receivable, net of reserves of $11,331 and $10,499

Ìý

716,529

Ìý

Ìý

Ìý

717,190

Ìý

Investments in and advances to unconsolidated joint ventures

Ìý

963,379

Ìý

Ìý

Ìý

936,814

Ìý

Accounts receivable, net of allowance of $1,932 and $2,243

Ìý

68,741

Ìý

Ìý

Ìý

76,810

Ìý

Cash and cash equivalents

Ìý

89,436

Ìý

Ìý

Ìý

119,818

Ìý

Restricted cash

Ìý

73,843

Ìý

Ìý

Ìý

64,487

Ìý

Intangible assets, net

Ìý

677,101

Ìý

Ìý

Ìý

817,254

Ìý

Assets held for sale, net

Ìý

45,717

Ìý

Ìý

Ìý

7,840

Ìý

Right-of-use asset, net

Ìý

426,631

Ìý

Ìý

Ìý

424,173

Ìý

Other assets, net

Ìý

928,836

Ìý

Ìý

Ìý

942,465

Ìý

Total assets

$

19,810,267

Ìý

Ìý

$

19,938,255

Ìý

Ìý

Ìý

Ìý

Ìý

Liabilities and Equity

Ìý

Ìý

Ìý

Bank line of credit and commercial paper

$

775,000

Ìý

Ìý

$

150,000

Ìý

Term loans

Ìý

1,646,605

Ìý

Ìý

Ìý

1,646,043

Ìý

Senior unsecured notes

Ìý

6,268,532

Ìý

Ìý

Ìý

6,563,256

Ìý

Mortgage debt

Ìý

351,116

Ìý

Ìý

Ìý

356,750

Ìý

Intangible liabilities, net

Ìý

166,352

Ìý

Ìý

Ìý

191,884

Ìý

Liabilities related to assets held for sale, net

Ìý

1,209

Ìý

Ìý

Ìý

�

Ìý

Lease liability

Ìý

310,099

Ìý

Ìý

Ìý

307,220

Ìý

Accounts payable, accrued liabilities, and other liabilities

Ìý

738,613

Ìý

Ìý

Ìý

725,342

Ìý

Deferred revenue

Ìý

965,800

Ìý

Ìý

Ìý

940,136

Ìý

Total liabilities

Ìý

11,223,326

Ìý

Ìý

Ìý

10,880,631

Ìý

Ìý

Ìý

Ìý

Ìý

Commitments and contingencies

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Redeemable noncontrolling interests

Ìý

20,104

Ìý

Ìý

Ìý

2,610

Ìý

Ìý

Ìý

Ìý

Ìý

Common stock, $1.00 par value: 1,500,000,000 shares authorized; 694,916,081 and 699,485,139 shares issued and outstanding

Ìý

694,916

Ìý

Ìý

Ìý

699,485

Ìý

Additional paid-in capital

Ìý

12,763,723

Ìý

Ìý

Ìý

12,847,252

Ìý

Cumulative dividends in excess of earnings

Ìý

(5,525,520

)

Ìý

Ìý

(5,174,279

)

Accumulated other comprehensive income (loss)

Ìý

(5,019

)

Ìý

Ìý

28,818

Ìý

Total stockholders� equity

Ìý

7,928,100

Ìý

Ìý

Ìý

8,401,276

Ìý

Ìý

Ìý

Ìý

Ìý

Joint venture partners

Ìý

298,597

Ìý

Ìý

Ìý

315,821

Ìý

Non-managing member unitholders

Ìý

340,140

Ìý

Ìý

Ìý

337,917

Ìý

Total noncontrolling interests

Ìý

638,737

Ìý

Ìý

Ìý

653,738

Ìý

Ìý

Ìý

Ìý

Ìý

Total equity

Ìý

8,566,837

Ìý

Ìý

Ìý

9,055,014

Ìý

Ìý

Ìý

Ìý

Ìý

Total liabilities and equity

$

19,810,267

Ìý

Ìý

$

19,938,255

Ìý

Ìý

Healthpeak Properties, Inc.

Consolidated Statements of Operations

In thousands, except per share data

Ìý

Ìý

Three Months Ended
June 30,

Ìý

Six Months Ended
June 30,

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Revenues:

Ìý

Ìý

Ìý

Ìý

Ìý

Rental and related revenues

$

529,687

Ìý

Ìý

$

546,781

Ìý

Ìý

$

1,067,828

Ìý

Ìý

$

1,008,814

Ìý

Resident fees and services

Ìý

148,855

Ìý

Ìý

Ìý

140,891

Ìý

Ìý

Ìý

297,782

Ìý

Ìý

Ìý

279,667

Ìý

Interest income and other

Ìý

15,806

Ìý

Ìý

Ìý

7,832

Ìý

Ìý

Ìý

31,627

Ìý

Ìý

Ìý

13,583

Ìý

Total revenues

Ìý

694,348

Ìý

Ìý

Ìý

695,504

Ìý

Ìý

Ìý

1,397,237

Ìý

Ìý

Ìý

1,302,064

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Costs and expenses:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Interest expense

Ìý

75,063

Ìý

Ìý

Ìý

74,910

Ìý

Ìý

Ìý

147,756

Ìý

Ìý

Ìý

135,817

Ìý

Depreciation and amortization

Ìý

265,916

Ìý

Ìý

Ìý

283,498

Ìý

Ìý

Ìý

534,462

Ìý

Ìý

Ìý

502,717

Ìý

Operating

Ìý

276,181

Ìý

Ìý

Ìý

273,827

Ìý

Ìý

Ìý

549,324

Ìý

Ìý

Ìý

517,556

Ìý

General and administrative

Ìý

20,764

Ìý

Ìý

Ìý

26,718

Ìý

Ìý

Ìý

46,882

Ìý

Ìý

Ìý

50,017

Ìý

Transaction and merger-related costs

Ìý

10,215

Ìý

Ìý

Ìý

7,759

Ìý

Ìý

Ìý

15,749

Ìý

Ìý

Ìý

114,979

Ìý

Impairments and loan loss reserves (recoveries), net

Ìý

3,499

Ìý

Ìý

Ìý

(553

)

Ìý

Ìý

(63

)

Ìý

Ìý

10,905

Ìý

Total costs and expenses

Ìý

651,638

Ìý

Ìý

Ìý

666,159

Ìý

Ìý

Ìý

1,294,110

Ìý

Ìý

Ìý

1,331,991

Ìý

Other income (expense):

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Gain (loss) on sales of real estate, net

Ìý

1,636

Ìý

Ìý

Ìý

122,044

Ìý

Ìý

Ìý

1,636

Ìý

Ìý

Ìý

125,299

Ìý

Other income (expense), net

Ìý

(4,692

)

Ìý

Ìý

4,004

Ìý

Ìý

Ìý

(10,818

)

Ìý

Ìý

82,520

Ìý

Total other income (expense), net

Ìý

(3,056

)

Ìý

Ìý

126,048

Ìý

Ìý

Ìý

(9,182

)

Ìý

Ìý

207,819

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures

Ìý

39,654

Ìý

Ìý

Ìý

155,393

Ìý

Ìý

Ìý

93,945

Ìý

Ìý

Ìý

177,892

Ìý

Income tax benefit (expense)

Ìý

(2,382

)

Ìý

Ìý

(2,728

)

Ìý

Ìý

(4,462

)

Ìý

Ìý

(16,426

)

Equity income (loss) from unconsolidated joint ventures

Ìý

1,747

Ìý

Ìý

Ìý

51

Ìý

Ìý

Ìý

(400

)

Ìý

Ìý

2,427

Ìý

Net income (loss)

Ìý

39,019

Ìý

Ìý

Ìý

152,716

Ìý

Ìý

Ìý

89,083

Ìý

Ìý

Ìý

163,893

Ìý

Noncontrolling interests� share in earnings

Ìý

(7,346

)

Ìý

Ìý

(6,669

)

Ìý

Ìý

(14,582

)

Ìý

Ìý

(11,170

)

Net income (loss) attributable to Healthpeak Properties, Inc.

Ìý

31,673

Ìý

Ìý

Ìý

146,047

Ìý

Ìý

Ìý

74,501

Ìý

Ìý

Ìý

152,723

Ìý

Participating securities� share in earnings

Ìý

(115

)

Ìý

Ìý

(214

)

Ìý

Ìý

(579

)

Ìý

Ìý

(414

)

Net income (loss) applicable to common shares

$

31,558

Ìý

Ìý

$

145,833

Ìý

Ìý

$

73,922

Ìý

Ìý

$

152,309

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Earnings (loss) per common share:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Basic

$

0.05

Ìý

Ìý

$

0.21

Ìý

Ìý

$

0.11

Ìý

Ìý

$

0.23

Ìý

Diluted

$

0.05

Ìý

Ìý

$

0.21

Ìý

Ìý

$

0.11

Ìý

Ìý

$

0.23

Ìý

Weighted average shares outstanding:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Basic

Ìý

695,188

Ìý

Ìý

Ìý

702,382

Ìý

Ìý

Ìý

697,117

Ìý

Ìý

Ìý

651,642

Ìý

Diluted

Ìý

695,194

Ìý

Ìý

Ìý

703,268

Ìý

Ìý

Ìý

697,146

Ìý

Ìý

Ìý

652,113

Ìý

Ìý

Healthpeak Properties, Inc.

Funds From Operations

In thousands, except per share data

Ìý

Ìý

Ìý

Three Months Ended
June 30,

Ìý

Six Months Ended
June 30,

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Net income (loss) applicable to common shares

Ìý

$

31,558

Ìý

Ìý

$

145,833

Ìý

Ìý

$

73,922

Ìý

Ìý

$

152,309

Ìý

AGÕæÈ˹ٷ½ estate related depreciation and amortization

Ìý

Ìý

265,916

Ìý

Ìý

Ìý

283,498

Ìý

Ìý

Ìý

534,462

Ìý

Ìý

Ìý

502,717

Ìý

Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures

Ìý

Ìý

12,530

Ìý

Ìý

Ìý

11,621

Ìý

Ìý

Ìý

24,730

Ìý

Ìý

Ìý

20,393

Ìý

Noncontrolling interests� share of real estate related depreciation and amortization

Ìý

Ìý

(4,426

)

Ìý

Ìý

(4,732

)

Ìý

Ìý

(8,879

)

Ìý

Ìý

(9,174

)

Loss (gain) on sales of depreciable real estate, net

Ìý

Ìý

(1,636

)

Ìý

Ìý

(122,044

)

Ìý

Ìý

(1,636

)

Ìý

Ìý

(125,299

)

Loss (gain) upon change of control, net(1)

Ìý

Ìý

�

Ìý

Ìý

Ìý

(198

)

Ìý

Ìý

�

Ìý

Ìý

Ìý

(77,978

)

Taxes associated with real estate dispositions(2)

Ìý

Ìý

(335

)

Ìý

Ìý

49

Ìý

Ìý

Ìý

(335

)

Ìý

Ìý

11,657

Ìý

Nareit FFO applicable to common shares

Ìý

Ìý

303,607

Ìý

Ìý

Ìý

314,027

Ìý

Ìý

Ìý

622,264

Ìý

Ìý

Ìý

474,625

Ìý

Distributions on dilutive convertible units and other

Ìý

Ìý

4,560

Ìý

Ìý

Ìý

4,583

Ìý

Ìý

Ìý

9,183

Ìý

Ìý

Ìý

5,281

Ìý

Diluted Nareit FFO applicable to common shares

Ìý

$

308,167

Ìý

Ìý

$

318,610

Ìý

Ìý

$

631,447

Ìý

Ìý

$

479,906

Ìý

Diluted Nareit FFO per common share

Ìý

$

0.43

Ìý

Ìý

$

0.44

Ìý

Ìý

$

0.89

Ìý

Ìý

$

0.72

Ìý

Weighted average shares outstanding - Diluted Nareit FFO

Ìý

Ìý

709,839

Ìý

Ìý

Ìý

717,797

Ìý

Ìý

Ìý

711,828

Ìý

Ìý

Ìý

661,999

Ìý

Impact of adjustments to Nareit FFO:

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Ìý

Transaction and merger-related items(3)

Ìý

$

10,215

Ìý

Ìý

$

3,369

Ìý

Ìý

$

15,749

Ìý

Ìý

$

106,198

Ìý

Other impairments (recoveries) and other losses (gains), net(4)

Ìý

Ìý

3,499

Ìý

Ìý

Ìý

(553

)

Ìý

Ìý

179

Ìý

Ìý

Ìý

11,300

Ìý

Casualty-related charges (recoveries), net(5)

Ìý

Ìý

3,919

Ìý

Ìý

Ìý

(1,204

)

Ìý

Ìý

8,145

Ìý

Ìý

Ìý

(1,204

)

Total adjustments

Ìý

Ìý

17,633

Ìý

Ìý

Ìý

1,612

Ìý

Ìý

Ìý

24,073

Ìý

Ìý

Ìý

116,294

Ìý

FFO as Adjusted applicable to common shares

Ìý

Ìý

321,240

Ìý

Ìý

Ìý

315,639

Ìý

Ìý

Ìý

646,337

Ìý

Ìý

Ìý

590,919

Ìý

Distributions on dilutive convertible units and other

Ìý

Ìý

4,545

Ìý

Ìý

Ìý

4,581

Ìý

Ìý

Ìý

9,161

Ìý

Ìý

Ìý

6,960

Ìý

Diluted FFO as Adjusted applicable to common shares

Ìý

$

325,785

Ìý

Ìý

$

320,220

Ìý

Ìý

$

655,498

Ìý

Ìý

$

597,879

Ìý

Diluted FFO as Adjusted per common share

Ìý

$

0.46

Ìý

Ìý

$

0.45

Ìý

Ìý

$

0.92

Ìý

Ìý

$

0.90

Ìý

Weighted average shares outstanding - Diluted FFO as Adjusted

Ìý

Ìý

709,839

Ìý

Ìý

Ìý

717,797

Ìý

Ìý

Ìý

711,828

Ìý

Ìý

Ìý

664,325

Ìý

_______________________________________

(1)

The six months ended June 30, 2024 includes a gain upon change of control related to the sale of a 65% interest in two lab buildings in San Diego, California. The gain upon change of control is included in other income (expense), net in the Consolidated Statements of Operations.

(2)

The six months ended June 30, 2024 includes non-cash income tax expense related to the sale of a 65% interest in two lab buildings in San Diego, California.

(3)

The three and six months ended June 30, 2025 and 2024 includes costs related to the merger, which are primarily comprised of advisory, legal, accounting, tax, information technology, post-combination severance and stock compensation expense, and other costs of combining operations with Physicians AGÕæÈ˹ٷ½ty Trust that were incurred during the period. The three and six months ended June 30, 2025 also includes $6 million of costs incurred related to investments we are no longer pursuing. For the three and six months ended June 30, 2024, these costs were partially offset by termination fee income of $4 million and $9 million, respectively, associated with Graphite Bio, Inc., which later merged with LENZ Therapeutics, Inc. in March 2024, for which the lease terms were modified to accelerate expiration of the lease to December 2024. This termination fee income is included in rental and related revenues on the Consolidated Statements of Operations, but is excluded from Portfolio Cash AGÕæÈ˹ٷ½ Estate Revenues and FFO as Adjusted.

(4)

The three and six months ended June 30, 2025 and 2024 include reserves and (recoveries) for expected loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations.

(5)

Casualty-related charges (recoveries), net are recognized in other income (expense), net, equity income (loss) from unconsolidated joint ventures, and noncontrolling interests' share in earnings in the Consolidated Statements of Operations.

Healthpeak Properties, Inc.

Adjusted Funds From Operations

In thousands, except per share data

Ìý

Ìý

Three Months Ended
June 30,

Ìý

Six Months Ended
June 30,

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

Ìý

Ìý

2025

Ìý

Ìý

Ìý

2024

Ìý

FFO as Adjusted applicable to common shares

$

321,240

Ìý

Ìý

$

315,639

Ìý

Ìý

$

646,337

Ìý

Ìý

$

590,919

Ìý

Stock-based compensation amortization expense

Ìý

1,738

Ìý

Ìý

Ìý

4,814

Ìý

Ìý

Ìý

6,365

Ìý

Ìý

Ìý

8,180

Ìý

Amortization of deferred financing costs and debt discounts (premiums)

Ìý

7,875

Ìý

Ìý

Ìý

7,317

Ìý

Ìý

Ìý

15,727

Ìý

Ìý

Ìý

11,840

Ìý

Straight-line rents

Ìý

(5,401

)

Ìý

Ìý

(10,453

)

Ìý

Ìý

(16,554

)

Ìý

Ìý

(22,545

)

AFFO capital expenditures

Ìý

(25,729

)

Ìý

Ìý

(35,718

)

Ìý

Ìý

(48,864

)

Ìý

Ìý

(53,235

)

CCRC entrance fees(1)

Ìý

19,042

Ìý

Ìý

Ìý

12,117

Ìý

Ìý

Ìý

23,739

Ìý

Ìý

Ìý

19,502

Ìý

Deferred income taxes

Ìý

2,597

Ìý

Ìý

Ìý

1,021

Ìý

Ìý

Ìý

5,168

Ìý

Ìý

Ìý

1,745

Ìý

Amortization of above (below) market lease intangibles, net

Ìý

(10,085

)

Ìý

Ìý

(8,086

)

Ìý

Ìý

(20,296

)

Ìý

Ìý

(15,437

)

Other AFFO adjustments

Ìý

(1,069

)

Ìý

Ìý

(2,169

)

Ìý

Ìý

381

Ìý

Ìý

Ìý

(3,667

)

AFFO applicable to common shares

Ìý

310,208

Ìý

Ìý

Ìý

284,482

Ìý

Ìý

Ìý

612,003

Ìý

Ìý

Ìý

537,302

Ìý

Distributions on dilutive convertible units and other

Ìý

4,560

Ìý

Ìý

Ìý

4,582

Ìý

Ìý

Ìý

9,182

Ìý

Ìý

Ìý

6,799

Ìý

Diluted AFFO applicable to common shares(1)

$

314,768

Ìý

Ìý

$

289,064

Ìý

Ìý

$

621,185

Ìý

Ìý

$

544,101

Ìý

Diluted AFFO per common share(1)

$

0.44

Ìý

Ìý

$

0.40

Ìý

Ìý

$

0.87

Ìý

Ìý

$

0.82

Ìý

Weighted average shares outstanding - Diluted AFFO

Ìý

709,839

Ìý

Ìý

Ìý

717,797

Ìý

Ìý

Ìý

711,828

Ìý

Ìý

Ìý

663,975

Ìý

_______________________________________

(1)

During the first quarter of 2025, we changed our definition of AFFO to adjust for the non-refundable entrance fees collected in excess of the related amortization as we believe the cash collection of these fees is a more meaningful representation of the performance of CCRCs in the determination of AFFO. Utilizing the prior definition for the three months ended June 30, 2025 and 2024, diluted AFFO applicable to common shares was $295.7 million and $276.9 million, respectively, and diluted AFFO per common share was $0.42 and $0.39, respectively. Utilizing the prior definition for the six months ended June 30, 2025 and 2024, diluted AFFO applicable to common shares was $597.4 million and $524.6 million, respectively, and diluted AFFO per common share was $0.84 and $0.79, respectively.

Ìý

Andrew Johns, CFA

Senior Vice President � Finance and Investor Relations

720-428-5400

Source: Healthpeak Properties, Inc.

Healthpeak Properties Inc

NYSE:DOC

DOC Rankings

DOC Latest News

DOC Latest SEC Filings

DOC Stock Data

11.97B
692.77M
0.27%
95.27%
2.22%
REIT - Healthcare Facilities
AGÕæÈ˹ٷ½ Estate Investment Trusts
United States
DENVER